Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
The future of Prescription Drug Affordability Boards (PDABs)
The effectiveness and impact of the UPL implementation for Enbrel will have a strong influence on how Maryland and other states proceed with their UPL...